Informatics for neglected diseases collaborations

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 3, 2010, Pages 286-296

  Bost, Frederic ^a   Jacobs, Robert T ^a   Kowalczyk, Paul ^a  

^a SCYNEXIS Inc   (United States)

Author keywords

Neglected diseases collaboration; public private partnership (PPP); Software as a Service (SaaS)

Indexed keywords

AMODIAQUINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ARTESUNATE; BENZNIDAZOLE; EFLORNITHINE; FEXINIDAZOLE; MEFLOQUINE; MILTEFOSINE; NIFURTIMOX; NITROIMIDAZOLE; PAROMOMYCIN;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; COMPUTER PROGRAM; CRYPTOSPORIDIOSIS; DRUG INFORMATION; DRUG RESEARCH; DRUG TARGETING; HEALTH PROGRAM; HUMAN; INFORMATION PROCESSING; INTERNET; INTERPERSONAL COMMUNICATION; MALARIA; MEDICAL INFORMATICS; MEDICAL RESEARCH; ORGANIZATION; PHENOTYPE; REVIEW; SCIENTIST; VISCERAL LEISHMANIASIS; WEB BROWSER;

COMMUNICABLE DISEASES; COMPUTER COMMUNICATION NETWORKS; COOPERATIVE BEHAVIOR; DATABASE MANAGEMENT SYSTEMS; DRUG DISCOVERY; HUMANS; INTERNATIONAL COOPERATION; INTERNATIONALITY; INTERNET; MEDICAL INFORMATICS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; SOFTWARE; TROPICAL MEDICINE;

EID: 77954067428     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N: Drug development for neglected diseases: A defcient market and a public-health policy failure. Lancet (2002) 359(9324):2188-2194.
2. Pink R, Hudson A, Mouriès MA, Bendig M: Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov (2005) 4(9):727-740.
3. Chatelain E, Ioset J-R: Drug discovery and development for neglected diseases: The DNDi model. In: Preclinical Drug Development: Genesis 2009. University of Greenwich, London, UK (2009):52-61.
4. Nwaka S, Hudson A: Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov (2006) 5(11):941-955.
5. Ribeiro I, Sevcsik A-M, Alves F, Diap G, Don R, Harhay MO, Chang S, Pecoul B: New, improved treatments for Chagas disease: From the R&D pipeline to the patients. PLoS Negl Trop Dis (2009) 3(7):e484.
6. Diseases covered by Neglected Tropical Diseases department: WHO, Geneva, Switzerland (2010). www.who.int/neglected-diseases/diseases/en/
7. Nwaka S, Ridley RG: Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov (2003) 2(11):919-928.
8. Croft SL: Public-private partnership: From there to here. Trans R Soc Trop Med Hyg (2005) 99(Suppl 1):S9-14.
9. Don R, Chatelain E: Drug Discovery for neglected diseases: View of a public-private partnership. In: Antiparasitic and Antibacterial Drug Discovery: From molecular targets to drug candidates. Selzer PM (Ed) Wiley-Blackwell, Hoboken, NJ, USA (2009):33-43.
10. Bathurst I, Hentschel C: Medicines for malaria venture: Sustaining antimalarial drug development. Trends Parasitol (2006) 22(7):301-307.
11. TB Alliance: Global Alliance for TB Drug Development: TB Alliance, New York, NY, USA (2010). www.tballiance.org
12. Institute for OneWorld Health: Fulflling the promises of medicine for the developing world: Institute for OneWorld Health, San Francisco, CA, USA (2010). www.oneworldhealth.org/
13. Accelerating malaria vaccine development: Malaria Vaccine Initiative, Bethesda, MD, USA (2010). www.malariavaccine.org/
14. FIND: Foundation for Innovative New Diagnostics: Foundation for Innovative New Diagnostics, Geneva, Switzerland (2010). www.fnddiagnostics.org/
15. Premji Z: Coartem: The journey to the clinic. Malaria J (2009) 8(Suppl 1):S3.
16. Herrling P: Experiments in social responsibility. Nature (2006) 439(7074):267-268.
17. Kettler HE, Marjanovic S: Engaging biotechnology companies in the development of innovative solutions for diseases of poverty. Nat Rev Drug Discov (2004) 3(2):171-176.
18. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K et al Identifcation of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430(7002):900-904.
19. Searls DB: Data integration: Challenges for drug discovery. Nat Rev Drug Discov (2005) 4(1):45-58.
20. Matter A, Keller TH: Impact of non-proft organizations on drug discovery: Opportunities, gaps, solutions. Drug Discov Today (2008) 13(7-8):347-352.
21. Burrows J: The state of the art in anti-malarial drug discovery and development. Current Topics in Medicinal Chemistry: in press.
22. Hopkins AL, Witty MJ, Nwaka S: Mission possible. Nature (2007) 449(7159):166-169.
23. Renslo AR, McKerrow JH: Drug discovery and development for neglected parasitic diseases. Nat Chem Biol (2006) 2(12): 701-710.
24. Wells TNC: New paradigms for drug discovery from parasitology. In: Preclinical Drug Development: Genesis 2009. University of Greenwich, London, UK (2009):39-45.
25. Herrling PL: Financing R&D for neglected diseases. Nat Rev Drug Discov (2009) 8(2):91.
26. Herrling P: Patent sense. Nature (2007) 449(7159):174-175.
27. Callan B, Gillespie I: The path to new medicines. Nature (2007) 449(7159):164-165.
28. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT et al: Genome sequence of the human malaria parasite falciparum. Nature (2002) 419(6906):498-511.
29. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, Lennard NJ, Caler E, Hamlin NE, Haas B, Bohme U et al: The genome of the African trypanosome Trypanosoma brucei. Science (2005) 309(5733):416-422.
30. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, Sisk E, Rajandream M-A, Adlem E, Aert R, Anupama A et al: The genome of the kinetoplastid parasite, Leishmania major. Science (2005) 309(5733):436-442.
31. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran A-N, Ghedin E, Worthey EA, Delcher AL, Blandin G, Westenberger SJ et al: The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science (2005) 309(5733):409-415.
32. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, Deng M, Liu C, Widmer G, Tzipori S, Buck GA et al Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 304(5669):441-445.
33. Comini MA, Guerrero SA, Haile S, Menge U, Lünsdorf H, Flohé L: Valdiation of Trypanosoma brucei trypanothione synthetase as drug target. Free Radic Biol Med (2004) 36(10): 1289-1302.
34. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AWE, Chen F, Crowther GJ et al: Genomic-scale prioritization of drug targets: The TDR targets database. Nat Rev Drug Discov (2008) 7(11): 900-907
35. The TDR Targets Database: Identifcation and ranking of targets against neglected tropical diseases: The TDR Drug Targets Network (2010). www.tdrtargets.org/
36. Aurrecoechea C, Brestelli J, Brunk BP, Fischer S, Gajria B, Gao X, Gingle A, Grant G, Harb OS, Heiges M, Innamorato F et al: EuPathDB: A portal to eukaryotic pathogen databases. Nucleic Acids Res (2010) 38(Database issue):D415-D419.
37. TriTryp Database: EuPathDB (2010). TriTrypDB.org
38. Desai PV, Patny A, Sabnis Y, Tekwani B, Gut J, Rosenthal P, Srivastava A, Avery M: Identifcation of novel parasitic cysteine protease inhibitors using virtual screening. 1. The chembridge database. J Med Chem (2004) 47(26):6609-6615.
39. Desai PV, Patny A, Gut J, Rosenthal PJ, Tekwani B, Srivastava A, Avery M: Identifcation of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem (2006) 49(5):1576-1584.
40. Mehta SR, Huang R, Yang M, Zhang X-Q, Kolli B, Chang K-P, Hoffman RM, Goto Y, Badaro R, Schooley RT: Real-time in vivo green fuorescent protein imaging of a murine leishmaniasis model as a new tool for leishmania vaccine and drug discovery. Clin Vaccine Immunol (2008) 15(12):1764-1770.
41. Williams AJ: A perspective of publicly accessible/open-access chemistry databases. Drug Discov Today (2008) 13(11-12): 495-501
42. Low-Hanging-Fruit: An antiparasitic drug database: University of California, San Francisco, CA, USA (2010). www.sandler.ucsf.edu/lhf/
43. Ertl P, Jelfs S: Designing drugs on the Internet? Free web tools and services supporting medicinal chemistry. Curr Top Med Chem (2007) 7(15):1491-1501.
44. Maurer SM, Rai A, Sali A: Finding cures for tropical diseases: Is open source an answer? PLoS Med (2004) 1(3):e56.
45. Pécoul B: Neglected diseases: Wake up! Medicus Mundi Schweiz Bulletin (2007) 103:36-41
46. Hit Explorer Operating System (HEOS): SCYNEXIS Inc, Research Triangle Park, NC, USA (2010). www.heos.com
47. Hohman M, Gregory K, Chibale K, Smith PJ, Ekins S, Bunin B: Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 14(5-6):261-270.
48. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R: Advancing drug innovation for neglected diseases-Criteria for lead progression. PLoS Negl Trop Dis (2009) 3(8):e440.
49. Lead discovery for infectious tropical diseases-2008 annual report. Special Programme for Research & Training in Tropical Diseases, Geneva, Switzerland (2009). apps.who.int/tdr/svc/publications/about-tdr/annual-reports/ lead-discovery-for-drugs-2008
50. Jacobs R, Nare B, Wring S, Bacchi C, Brun R, Plattner J, Beaudet B, Bowling T, Chen D, Freund Y, Gaukel E et al: Effcacy and pharmacokinetics of SCYX-7158 (AN 5568): A novel and potent oxaborole-6-carboxamide selected as a pre-clinical candidate for once-daily oral treatment for stage 2 human African trypanosomiasis. Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, USA (2009) 58:Abs 2980.
51. ActivityBase Suite: ID Business Solutions Ltd, Guildford, UK (2010). www.idbs.com/activitybase/
52. Hassan M, Brown R, Varma-O'Brien S, Rogers D: Cheminformatics analysis and learning in a data pipelining environment. Mol Divers (2006) 10(3):283-299.
53. TIBCO Spotfre: Tibco Software Inc, Somerville, MA, USA (2010). spotfre.tibco.com/
54. The R project for statistical computing: The R Foundation, Vienna, Austria (2009). www.R-project.org
55. Barber CG, Haque N, Gardner B: 'One point'-Combining OneNote and SharePoint to facilitate knowledge transfer. Drug Discov Today (2009) 14(17-18):845-850.
56. Williams AJ: Internet-based tools for communication and collaboration in chemistry. Drug Discov Today (2008) 13(11-12):502-506.
57. Java A, Song X, Finin T, Tseng B: Why we twitter: Understanding microblogging usage and communities. Joint 9th WebKDD and 1st SNA-KDD 2007 workshop: Web mining and social network analysis, San Jose, CA, USA (2007):Abs ID21.
58. Acquisti A, Gross R: Imagined communities awareness, information sharing, and privacy on the facebook. Workshop on Privacy Enhancing Technologies, Cambridge, UK (2006) 6:36-58.
59. Debatin B, Lovejoy JP, Horn A-K, Hughes BN: Facebook and online privacy: Attitudes, behaviors, and unintended consequences. J Comput-Mediat Commun (2009) 15(1):83-108.
60. Ellison NB, Steinfeld C, Lampe C: The benefts of facebook "friends:" Social capital and college students' use of online social network sites. J Comput-Mediat Commun (2007) 12(4): 1143-1168.
61. Bailey DS, Zanders ED: Drug discovery in the era of Facebook new tools for scientifc networking. Drug Discov Today (2008) 13(19-20):863-868
62. Orchid neglected diseases drug development community: LinkedIn Corp, Mountain View, CA, USA. www.linkedin.com/groups?home=&gid=1783204&trk= anet-ug-hm
63. Warr W: A grand vision for confgurable science and minimizing the loss model. J Comput Aided Mol Des (2008) 22(8):587-591
64. ChemBioConnect: Collaborative visual chemistry research tool: Imaginatik plc, Boston, MA, USA (2010). www.imaginatik.com/webdoc-prod-chembioconnect
65. Symyx Solutions Inc: Symyx announces ChemMobi application now available on app store. Press Release (2009): July 23. www.symyx.com/company/news/press- releases/2009/pr-chemmobi-app-store.jsp
66. Welcome to ChemJuice: ID Business Solutions Ltd, Guildford, UK (2010). www.idbs.com/ChemJuice/
67. Salesforce Chatter: Salesforce.com Inc, San Francisco, CA, USA (2010). www.salesforce.com/chatter
68. Skeels MM, Grudin J: When social networks cross boundaries: A case study of workplace use of Facebook and LinkedIn. In: Proceedings of the ACM 2009 International Conference on Supporting Group Work. Association for Computing Machinery, New York, NY, USA (2009):95-104.
69. Strategic and business plan for the African Network for Drug and Diagnostics Innovation (ANDI): WHO, Geneva, Switzerland (2009). meeting.tropika.net/andi2009/fles/2009/10/sbp-fnal-web.pdf
70. Pécoul B: Interview with Dr Bernard Pécoul, Executive Director of the Drugs for Neglected Diseases initiative. Future Medicinal Chemistry (2009) 1(2):243-248.